Sodium chloride Fresenius Kabi 0,9% infuzní roztok, Cerebrolysin 215,2mg/ml Injekční roztok
Phase 2 small_molecule active
Quick answer
Sodium chloride Fresenius Kabi 0,9% infuzní roztok, Cerebrolysin 215,2mg/ml Injekční roztok for Cerebral Autosomal Dominant Arteriopathy with subcortical Infarcts and Leukoencephalopathy (CADASIL) is a Phase 2 program (small_molecule) at Lacuna Pharma Pty Ltd with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Lacuna Pharma Pty Ltd
- Indication
- Cerebral Autosomal Dominant Arteriopathy with subcortical Infarcts and Leukoencephalopathy (CADASIL)
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active